The CGTLive™ Ophthalmology specialty topic page includes the most recent clinical care news related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for disorders and diseases of the eye. It also contains video interviews with key opinion leaders in the field of ophthalmology discussing related FDA actions, clinical guideline updates, and clinical trial findings in the field of gene and cell therapy for ophthalmic conditions.
December 4th 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
LCA1 Gene Therapy ATSN-101 Shows Phase 1/2 Promise at Highest Dose Assessed
April 4th 2023Atsena Therapeutics’ AAV gene therapy is being evaluated in 15 patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D across 5 cohorts of various doses. Additional data are expected to be presented later this year.